Brittany G. Craiglow

Featured in: Favicon

jamanetwork.com Favicon

aap.org

hcplive.com Favicon

mdedge.com Favicon

hmpgloballearningnetwork.com Favicon

jaad.org

contemporarypediatrics.com Favicon

dermatologytimes.com Favicon

jofskin.org Favicon

jaadcasereports.org + 2 more

Articles

Baricitinib Shows Promise for Pediatric Alopecia in BRAVE-AA-PEDS Study

1 month ago | ajmc.com | Cameron Santoro |Brittany G. Craiglow

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut, discussed the promise of combination therapy to treat pediatric alopecia areata, specifically focusing on the use of baricitinib in adolescents with severe cases.
Baricitinib effective in adolescents with severe alopecia areata, phase 3 data show

1 month ago | healio.com | Stephanie Viguers |Kristen Dowd |Brittany G. Craiglow

Key takeaways: 42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying treatment in this population. ORLANDO — Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and eyelashes compared with placebo in adolescents with severe alopecia areata, data show.
Future Directions in the Treatment of Alopecia Areata

Dec 2, 2024 | hcplive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow

OpinionVideoDecember 2, 2024Author(s):, JAK inhibitors provide targeted treatment for alopecia by modulating immune pathways, offering a promising therapeutic option. Patient-specific factors, such as disease severity and comorbidities, should guide the selection of JAK inhibitors. Monitoring for potential side effects, including infections and hematologic abnormalities, is crucial in JAK inhibitor therapy. Collaboration with dermatologists can enhance treatment outcomes in alopecia management.
The Role of Health Care Providers in Raising Awareness About Alopecia Areata

Dec 2, 2024 | consultantlive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow
Future Directions in the Treatment of Alopecia Areata

Dec 2, 2024 | consultantlive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow
The Role of Health Care Providers in Raising Awareness About Alopecia Areata

Dec 2, 2024 | hcplive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow

OpinionVideoDecember 2, 2024Author(s):, Healthcare providers are essential in educating patients about alopecia's early signs and treatment options, promoting awareness and understanding. Integrating alopecia discussions into routine check-ups and using educational materials can effectively inform patients about the condition. Emphasizing early diagnosis and intervention can lead to more effective management of alopecia, improving patient outcomes.
Challenges With the Use of JAK Inhibitors

Nov 25, 2024 | hcplive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow

OpinionVideoNovember 25, 2024Author(s):, Patient selection is critical, as response to oral JAK inhibitors varies among individuals with alopecia. Monitoring for side effects, including infection risk and blood count changes, is essential for safe use. Limited long-term safety data necessitates cautious use and further research into oral JAK inhibitors. Cost and insurance coverage challenges can hinder patient access to these treatments.
Considerations Regarding Patient Selection for JAK Inhibitors

Nov 25, 2024 | consultantlive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow
Considerations Regarding Patient Selection for JAK Inhibitors

Nov 25, 2024 | hcplive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow

OpinionVideoNovember 25, 2024Author(s):, JAK inhibitors are effective for moderate to severe alopecia, especially in patients unresponsive to conventional therapies. Ideal candidates are those with significant hair loss affecting quality of life. Caution is necessary for patients with malignancies, active infections, or immunocompromised status due to immune modulation. Patients with thromboembolic history or cardiovascular risks need thorough evaluation before treatment initiation.
Challenges With the Use of JAK Inhibitors

Nov 25, 2024 | consultantlive.com | Arash Mostaghimi |Amy J. McMichael |Brittany G. Craiglow